More deals imminent!, page-20

From AGM presentation 2018

Our focus is on deal closure –
ZolpiMist: continue to develop the global brand by expanding the geographic territories covered by licensing deals –
Sumatriptan: expand territories covered. –
ArTiMist: Leverage the TGA approval to finalise deal –
Anagrelide: Continue the industry exposure and launch BD activities in earnest –
Midazolam: complete PoC study and convert the strong current interest into deals –
Cannabinoids: Finalise current negotiations and sign deal. –
Co-Development: Complete at least 2 further co-development deals. –
Others: continue to move programs forward to close deals. •
Close deal- strengthens balance sheet and extends cash runway.

From AGM Presentation 2017

NEXT STEPS
✓ ZolpiMist deals in Europe and elsewhere
✓ Further partnering deals with SUDA’s other candidates
✓ Monetisation of ArTiMist
✓ Expansion of Pfizer collaboration
✓ More co-development partnerships
✓ Early sales success by ZolpiMist partners
✓ Approval of ZolpiMIst in Australia, China, LatAm and Europe